All patients
Asian type cell type, adenocarcinoma cell ECOG ⩾ 1 ECOG 0 EGFR mutant EGFR negative EGFR positive EGFR wild type Gender, female Gender, male RAS mutant RAS wild type smoker (current or former) smoker (Current) smoker (Former) smoker (never) stage IIIb stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
mNSCLC - L2 - all population, ... vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results A7471028, 2012 (REV) 1.25 [0.88; 1.78]
ARCHER 1009 (all population), 2014 (REV) 0.93 [0.78; 1.09]
DELTA, 2014 0.91 [0.68; 1.22]
NCIC CTG BR.21, 2005 0.70 [0.58; 0.85]
WJOG 5108L, 2016 (REV) 0.96 [0.77; 1.20]
ZEST, 2011 (REV) 1.03 [0.91; 1.17]
0.93 [0.81 ; 1.07 ] A7471028, 2012 (REV), ARCHER 1009 (all population), 2014 (REV), DELTA, 2014, NCIC CTG BR.21, 2005, WJOG 5108L, 2016 (REV), ZEST, 2011 (REV) 6 64% 3,897 moderate not evaluable progression or deaths (PFS)detailed results A7471028, 2012 (REV) 1.52 [1.09; 2.11]
ARCHER 1009 (all population), 2014 (REV) 1.06 [0.91; 1.25]
DELTA, 2014 1.22 [0.97; 1.54]
NCIC CTG BR.21, 2005 0.61 [0.51; 0.73]
WJOG 5108L, 2016 (REV) 0.89 [0.74; 1.06]
ZEST, 2011 (REV) 1.02 [0.91; 1.15]
1.00 [0.81 ; 1.22 ] A7471028, 2012 (REV), ARCHER 1009 (all population), 2014 (REV), DELTA, 2014, NCIC CTG BR.21, 2005, WJOG 5108L, 2016 (REV), ZEST, 2011 (REV) 6 87% 3,897 moderate not evaluable DCRdetailed results WJOG 5108L, 2016 (REV) 0.98 [0.70; 1.38]
0.98 [0.70 ; 1.38 ] WJOG 5108L, 2016 (REV) 1 0% 559 NA not evaluable objective responses (ORR)detailed results A7471028, 2012 (REV) 0.27 [0.10; 0.78]
ARCHER 1009 (all population), 2014 (REV) 0.69 [0.44; 1.09]
DELTA, 2014 0.96 [0.53; 1.76]
NCIC CTG BR.21, 2005 10.18 [2.43; 42.54]
WJOG 5108L, 2016 (REV) 0.93 [0.65; 1.33]
ZEST, 2011 (REV) 1.00 [0.71; 1.40]
0.93 [0.61 ; 1.42 ] A7471028, 2012 (REV), ARCHER 1009 (all population), 2014 (REV), DELTA, 2014, NCIC CTG BR.21, 2005, WJOG 5108L, 2016 (REV), ZEST, 2011 (REV) 6 72% 3,809 moderate not evaluable TRAE (any grade)detailed results ARCHER 1009 (all population), 2014 (REV) 0.56 [0.34; 0.94]
0.56 [0.34 ; 0.94 ] ARCHER 1009 (all population), 2014 (REV) 1 0% 872 NA not evaluable TRAE (grade 3-4)detailed results ARCHER 1009 (all population), 2014 (REV) 0.60 [0.44; 0.81]
0.60 [0.44 ; 0.81 ] ARCHER 1009 (all population), 2014 (REV) 1 0% 872 NA not evaluable TRAE leading to death (grade 5)detailed results A7471028, 2012 (REV) 0.99 [0.14; 7.17]
ARCHER 1009 (all population), 2014 (REV) 0.25 [0.03; 2.23]
0.53 [0.12 ; 2.32 ] A7471028, 2012 (REV), ARCHER 1009 (all population), 2014 (REV) 2 0% 1,059 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results A7471028, 2012 (REV) 0.27 [0.05; 1.32]
0.27 [0.05 ; 1.32 ] A7471028, 2012 (REV) 1 0% 187 NA not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-06 10:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 37
- treatments: 430
